To our knowledge, this is the first study to assess prognostic factors in the clinically relevant entities of IDH-mutated astrocytoma and oligodendroglioma, respectively, without known CDKN2A/B homozygous deletions. The gene discussed is CDKN2A; the disease is oligodendroglioma.